ReviewDrug delivery and translational research2025
Plant-based flavonoids and their nanoparticles: Latest arsenal against Alzheimer's disease.
Review in Drug delivery and translational research, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
13 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Alzheimer's disease (AD) is the most prevalent and emerging neurodegenerative disease and serves as the seventh biggest cause of mortality across the globe. The pathogenesis of AD is linked with multiple hallmarks. The applications of anti-AD therapeutics approved by the FDA have been restricted because of the least permeability, bioavailability, negative effects, and huge cost. Various flavonoids have attenuated the potential pathogenic biomarkers of Alzheimer's disease (AD) and reduced disease progression. However, the presence of the blood-brain barrier (BBB), limited permeability, bioavailability, and low stability are chief concerns associated with their delivery against AD. Therefore, they have been loaded into various nanoformulations, including PLGA nanoparticles, gold nanoparticles, NLCs, exosomes, cell membrane-coated nanocarriers, and microneedles, to improve brain targeting and enhance therapeutic effects at the site of action. This review focuses on the flavonoid as a potential natural therapeutics against AD. Diverse flavonoids explored to manage AD are discussed with their multiple anti-AD mechanisms. AD pathophysiology, current treatment strategies and its challenges, and the significance of using flavonoids against AD are explained. Moreover, role of NSCs in AD and potential of flavonoids in targeting NSCs is briefed. Challenges in the delivery of flavonoids against AD and diverse ground-breaking nanotechnological strategies employed to deliver these flavonoid-based therapeutics are discussed with manifold case studies. Also, the mechanisms of transport of NCs are explained. Further, flavonoids in clinical trials are briefed with conclusions and future concerns. In conclusion, flavonoid-based therapeutics and their delivery using breakthrough nanotechnological approaches hold promise for successfully managing AD.
Indexed as
Identifiers
40587047What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.